Jessica R. May
Bristol, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis.
Journal: Immuno-oncology technology
Published: March 17, 2025
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
Journal: Journal of medical economics
Published: August 26, 2023
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma.
Journal: Journal of comparative effectiveness research
Published: July 11, 2023
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.
Journal: PharmacoEconomics - open
Published: January 24, 2023
Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China.
Journal: PharmacoEconomics - open
Published: December 04, 2022
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
Journal: European urology oncology
Published: September 21, 2022
A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: May 09, 2022
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Journal: Current medical research and opinion
Published: July 24, 2018
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Journal: Journal of managed care & specialty pharmacy
Published: May 26, 2018
Functionalized poly(γ-Glutamic Acid) fibrous scaffolds for tissue engineering.
Journal: Advanced healthcare materials
Published: February 07, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026